Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
SNSS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.29%80.010.9%$589.41m
CELGCelgene Corporation
-1.22%137.171.1%$556.07m
AMGNAmgen Inc.
0.05%186.281.1%$452.39m
BIIBBiogen Inc.
0.03%344.581.2%$391.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.72%439.372.7%$313.54m
ALNYAlnylam Pharmaceuticals, Inc
-0.97%117.5510.7%$253.20m
VRTXVertex Pharmaceuticals Incorporated
-0.12%154.861.9%$219.44m
INCYIncyte Corporation
-0.43%115.142.5%$206.28m
ALXNAlexion Pharmaceuticals, Inc.
-2.04%140.241.9%$178.91m
ILMNIllumina, Inc.
-0.42%205.623.5%$138.87m
EXELExelixis, Inc.
-2.72%27.536.5%$135.05m
BLUEBluebird Bio, Inc.
-0.79%139.1017.3%$114.78m
BMRNBioMarin Pharmaceutical Inc.
-5.26%88.624.4%$108.97m
CLVSClovis Oncology, Inc.
-3.20%78.7216.5%$108.85m
SRPTSarepta Therapeutics, Inc.
-0.58%51.4216.9%$107.58m

Company Profile

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.